What Is Ipamorelin?

Ipamorelin is a small synthetic peptide, just five residues, that belongs to the growth-hormone-releasing peptides. Where a GHRH analogue mimics the natural releasing hormone, ipamorelin works through a separate route, the ghrelin receptor. This profile describes the molecule, the receptor it acts on, and the research it appears in, and makes no statement about use.

Ipamorelin came from work on short peptides that engage the growth-hormone secretagogue receptor, the receptor also known as the ghrelin receptor. Its compact five-residue design was of interest in that research partly because reports described it as comparatively selective in laboratory settings, acting on its target with limited effect on several other measured signals. The synthetic route behind peptides of this length is outlined in solid-phase peptide synthesis.

Ipamorelin is a pentapeptide, five amino acids in a defined order, which makes it small and comparatively straightforward to synthesise and characterise. The material is handled as a lyophilised powder, as listed on the ipamorelin product page; for the residue building blocks, our note on amino acid classifications gives the background.

Interest in ipamorelin centres on the ghrelin receptor and on the reported selectivity that makes it useful as a probe. A molecule that engages one secretagogue receptor cleanly gives researchers a way to study that receptor on its own terms. The complementary GHRH-analogue class is profiled in what is CJC-1295?, and the two are commonly examined side by side because they reach the same broad pathway by different doors.

The ghrelin receptor, formally the growth-hormone secretagogue receptor, is the target that defines this class, and it is also engaged by the body’s own ghrelin. Studying a defined synthetic agonist at that receptor lets researchers separate the receptor’s contribution to secretagogue signalling from the GHRH route, which is one reason ipamorelin and a GHRH analogue are so often examined as a pair. A short, comparatively selective agonist is a clean instrument for that purpose, since fewer off-target signals mean a clearer read on the receptor under study.

Published study places ipamorelin in growth-hormone secretagogue and ghrelin-receptor research: how it binds and activates the receptor, how its small structure relates to that activity, and how it behaves alongside GHRH analogues in model systems. These describe the molecule in research settings only. Related secretagogue materials sit in the research catalogue.

A recurring strand of this work asks how a sequence as short as five residues achieves activity at the ghrelin receptor at all, which connects structure to function in an unusually direct way. Because the peptide is small, that relationship can be probed by relating defined structural features to measured receptor activity, making ipamorelin a convenient subject for structure-activity study within the secretagogue class.

Ipamorelin is one of several growth-hormone-releasing peptides, and its reported selectivity is the feature that most often sets it apart in the literature. The ipamorelin research overview takes up the receptor mechanisms and the limits of the evidence.

All products are supplied strictly for laboratory research use only. Not for human or animal consumption. Not a drug, supplement, or food. Not for diagnostic or therapeutic use. The material on this page is educational and factual: it summarises areas of published scientific investigation and general laboratory practice. It is not guidance for the use of any material in humans or animals, and nothing here should be read as a claim about safety, performance, or outcomes. Where a specific product specification or safety data sheet is provided with a material, that document is the definitive reference and takes precedence over any general information given here.